NOVATO, Calif., June 13, 2024 Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare.
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare